These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 23088650)

  • 1. Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial.
    Zinzani PL; Khuageva NK; Wang H; Garicochea B; Walewski J; Van Hoof A; Soubeyran P; Caballero D; Buckstein R; Esseltine DL; Theocharous P; Enny C; Zhu E; Elsayed YA; Coiffier B
    J Hematol Oncol; 2012 Oct; 5():67. PubMed ID: 23088650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
    Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
    Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.
    Baiocchi RA; Alinari L; Lustberg ME; Lin TS; Porcu P; Li X; Johnston JS; Byrd JC; Blum KA
    Cancer; 2011 Jun; 117(11):2442-51. PubMed ID: 24048792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.
    Craig M; Hanna WT; Cabanillas F; Chen CS; Esseltine DL; Neuwirth R; O'Connor OA
    Br J Haematol; 2014 Sep; 166(6):920-8. PubMed ID: 25039282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
    Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT; Lechowicz MJ; Lonial S; Flowers CR
    Cancer; 2012 Jul; 118(14):3538-48. PubMed ID: 22535574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
    de Vos S; Goy A; Dakhil SR; Saleh MN; McLaughlin P; Belt R; Flowers CR; Knapp M; Hart L; Patel-Donnelly D; Glenn M; Gregory SA; Holladay C; Zhang T; Boral AL
    J Clin Oncol; 2009 Oct; 27(30):5023-30. PubMed ID: 19770386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab.
    Coiffier B; Li W; Henitz ED; Karkera JD; Favis R; Gaffney D; Shapiro A; Theocharous P; Elsayed YA; van de Velde H; Schaffer ME; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Romejko-Jarosinska J; de Vos S; Crump M; Shpilberg O; Zinzani PL; Cakana A; Esseltine DL; Mulligan G; Ricci D
    Clin Cancer Res; 2013 May; 19(9):2551-61. PubMed ID: 23549871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
    Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study.
    Evens AM; Smith MR; Lossos IS; Helenowski I; Millenson M; Winter JN; Rosen ST; Gordon LI
    Br J Haematol; 2014 Aug; 166(4):514-20. PubMed ID: 24761968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.
    Fowler N; Kahl BS; Lee P; Matous JV; Cashen AF; Jacobs SA; Letzer J; Amin B; Williams ME; Smith S; Saleh A; Rosen P; Shi H; Parasuraman S; Cheson BD
    J Clin Oncol; 2011 Sep; 29(25):3389-95. PubMed ID: 21810687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.
    Friedberg JW; Vose JM; Kelly JL; Young F; Bernstein SH; Peterson D; Rich L; Blumel S; Proia NK; Liesveld J; Fisher RI; Armitage JO; Grant S; Leonard JP
    Blood; 2011 Mar; 117(10):2807-12. PubMed ID: 21239695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS).
    Morschhauser F; Mounier N; Sebban C; Brice P; Solal-Celigny P; Tilly H; Feugier P; Fermé C; Copin MC; Lamy T
    Cancer; 2010 Sep; 116(18):4299-308. PubMed ID: 20549824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.
    Gerecitano J; Portlock C; Hamlin P; Moskowitz CH; Noy A; Straus D; Schulman P; Dumitrescu O; Sarasohn D; Pappanicholaou J; Iasonos A; Zhang Z; Mo Q; Horanlli E; Rojas CN; Zelenetz AD; O'Connor OA
    Clin Cancer Res; 2011 Apr; 17(8):2493-501. PubMed ID: 21346146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).
    Martin P; Jung SH; Pitcher B; Bartlett NL; Blum KA; Shea T; Hsi ED; Ruan J; Smith SE; Leonard JP; Cheson BD
    Ann Oncol; 2017 Nov; 28(11):2806-2812. PubMed ID: 28945884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.
    Sehn LH; MacDonald D; Rubin S; Cantin G; Rubinger M; Lemieux B; Basi S; Imrie K; Gascoyne RD; Sussman J; Chen BE; Djurfeldt M; Shepherd L; Couban S; Crump M
    J Clin Oncol; 2011 Sep; 29(25):3396-401. PubMed ID: 21810681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.
    Czuczman MS; Leonard JP; Jung S; Johnson JL; Hsi ED; Byrd JC; Cheson BD
    Ann Oncol; 2012 Sep; 23(9):2356-2362. PubMed ID: 22357442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.
    Agathocleous A; Rohatiner A; Rule S; Hunter H; Kerr JP; Neeson SM; Matthews J; Strauss S; Montoto S; Johnson P; Radford J; Lister A
    Br J Haematol; 2010 Nov; 151(4):346-53. PubMed ID: 20880120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.
    Ghobrial IM; Hong F; Padmanabhan S; Badros A; Rourke M; Leduc R; Chuma S; Kunsman J; Warren D; Harris B; Sam A; Anderson KC; Richardson PG; Treon SP; Weller E; Matous J
    J Clin Oncol; 2010 Mar; 28(8):1422-8. PubMed ID: 20142586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.
    Tilly H; Morschhauser F; Casasnovas O; Molina TJ; Feugier P; Gouill SL; Haioun C; Tournilhac O; Bouabdallah R; Gabarre J; Lamy T; Cabeçadas J; Becker S; Jardin F; Mounier N; Salles G;
    Lancet Haematol; 2018 Sep; 5(9):e403-e410. PubMed ID: 30172345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.
    Lamm W; Kaufmann H; Raderer M; Hoffmann M; Chott A; Zielinski C; Drach J
    Haematologica; 2011 Jul; 96(7):1008-14. PubMed ID: 21486866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.